Welcome to Our Site
Our site provides investors with company-
specific data on publicy traded Israeli
stocks in Tel Aviv, Israeli companies
traded globally as well as up-to-date
information on Israel and its economy.
Haaretz.com, 16/4/2014 - Delek Group off-loading overseas assetsRead More >>
Globes, 16/4/2014 - Teva launches generic insomnia treatment in USRead More >>
Brand Lunesta had $852 million in US sales in 2013.
Globes, 16/4/2014 - Cellcom picks Nokia Solutions for 4G networkRead More >>
Cellcom expects wide and high quality network deployment by the end of the year.
Globes, 9/4/2014 - Teva tax break in 2012 climbs to NIS 3.2bRead More >>
This is the largest ever tax break received by a single Israeli company.
Teva - PM Cameron visit Teva
Evogene - Evogen, Monsanto and Sygenta
RedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film >>
Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntingtons Disease >>
Kamada Announces Significantly Improved Infusion Rate for Glassia® >>
Partner Communications Announces Receiving a Lawsuit and a Motion for the Recognition of This Lawsuit as a Class Action >>
BrainStorm Cell Therapeutics
BrainStorm Hosting Conference Call to Update Shareholders on Important Developments >>
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE® Patent Due to the Potential for the Company to Recover Patent Infringement Damages >>
Teva Settles Patent Litigation with Pfizer on Celebrex® >>
Delek Group's Subsidiary sells Delek Europe BV to Foriegn Fund For 355 Million >>
Reprinted from the Equities Israel web site - www.equities.co.il